New Market Research Report: Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2012

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research
By: Fast Market Research, Inc.
 
 
Spread the Word
Listed Under

Tags:
h2
Purpura
Thrombocytopenic

Industry:
Medical

Location:
Massachusetts - US

Oct. 11, 2012 - PRLog -- Global Markets Direct's, 'Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura. Thrombotic Thrombocytopenic Purpura - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/468424_thrombotic_thrombocytopenic_purpura_pipeline.aspx
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Thrombotic Thrombocytopenic Purpura.
* A review of the Thrombotic Thrombocytopenic Purpura products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Thrombotic Thrombocytopenic Purpura pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Thrombotic Thrombocytopenic Purpura.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thrombotic Thrombocytopenic Purpura Overview
Therapeutics Development
An Overview of Pipeline Products for Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura Therapeutics under Development by Companies
Thrombotic Thrombocytopenic Purpura Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Thrombotic Thrombocytopenic Purpura Therapeutics - Products under Development by Companies
Thrombotic Thrombocytopenic Purpura Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Thrombotic Thrombocytopenic Purpura Therapeutics Development
Ablynx
Glenmark Pharmaceuticals Ltd.
Octapharma AG
Thrombotic Thrombocytopenic Purpura - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALX-0081 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0681 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
danazol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cyclosporine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Uniplas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GBR-600 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0081 + ALX-0681 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thrombotic Thrombocytopenic Purpura Therapeutics - Drug Profile Updates
Thrombotic Thrombocytopenic Purpura Therapeutics - Discontinued Products
Thrombotic Thrombocytopenic Purpura Therapeutics - Dormant Products
Thrombotic Thrombocytopenic Purpura - Product Development Milestones
Featured News & Press Releases
Apr 16, 2012: Baxter And Halozyme Provide Update On HyQ Biologics License Application
Jul 28, 2011: Initial Observations Of ABLYNX'S PHASE II TTP Program Presented At ISTH Congress
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0081
Sep 30, 2010: Ablynx Initiates Phase II Clinical Trial For ALX-0681
Aug 27, 2010: Octapharma Successfully Completes Uniplas Clinical Development
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Thrombotic Thrombocytopenic Purpura, H2 2012
Products under Development for Thrombotic Thrombocytopenic Purpura - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Pre-Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4684...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.
End
Email:***@fastmr.com Email Verified
Phone:1.800.844.8156
Zip:01267
Tags:h2, Purpura, Thrombocytopenic
Industry:Medical
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share